#WeCare and #MECFA advance CF care in the Middle East
“to improve and extend the lives of Cystic Fibrosis patients through disease awareness, advocacy and advanced care." MECFA The Middle...
#NACFC2018 — Vertex Presents Latest Clinical Data on CFTR Modulators
Vertex Pharmaceuticals’ VX-659 or VX-445 in combination with Kalydeco(ivacaftor) and tezacaftor (VX-661) can improve the lung function of...
PTI-808 and PTI-801 Combo Improves Lung Function in CF Patients, Phase 1 Data Show
Treatment with a combo of Proteostasis Therapeutics’ investigational CFTR modulator therapies — PTI-808, a potentiator, plus PTI-801, a...
#NACFC2018 — Celtaxsys’ Acebilustat Delays Onset, Reduces Rate of Pulmonary Exacerbations in CF, Pha
Once-daily acebilustat, an investigational oral therapy for cystic fibrosis (CF) under development by Celtaxsys, reduces the frequency...
Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Pres
Pre-clinical findings show RPL554 stimulates rare class III and IV CFTR mutants Phase 2a results demonstrate RPL554 has favorable...
Proteostasis Therapeutics' Double and Triple-Combo CF Drugs Possible Threat to Vertex Dominance
Boston-based Proteostasis Therapeutics announced positive preliminary data from its ongoing Phase I clinical trial of PTI-808 and PTI-801...